Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212)

V. L. Stauffer; D. W. Dodick; Q. Zhang; J. N. Carter; J. Ailani; R. R. Conley

doi:10.1001/jamaneurol.2019.1177

Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212)

V. L. Stauffer, D. W. Dodick, Q. Zhang, J. N. Carter, J. Ailani, R. R. Conley

Neurology

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

Error in Table: In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine:TheEVOLVE-1RandomizedClinicalTrial,"1 published onlineMay29,2018, therewas anerror inTable 1. In the 14th rowof the table, "Patients with acute medicationoveruse," thenumberandpercentagevalues should read "87 (20.2)" for the Placebo column; "39 (18.3)" for the Galcanezumab, 120 mg, column; and "42 (19.8)" for the Galcanezumab, 240mg, column. This article was corrected online.

Original language	English (US)
Pages (from-to)	872
Number of pages	1
Journal	JAMA neurology
Volume	76
Issue number	7
DOIs	https://doi.org/10.1001/jamaneurol.2019.1177
State	Published - Jul 2019

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1001/jamaneurol.2019.1177

Cite this

Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212). / Stauffer, V. L.; Dodick, D. W.; Zhang, Q. et al.
In: JAMA neurology, Vol. 76, No. 7, 07.2019, p. 872.

Research output: Contribution to journal › Comment/debate › peer-review

@article{e875fa3a2ee94e04b75aca6c57dabce9,

title = "Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212)",

abstract = "Error in Table: In the Original Investigation titled {"}Evaluation of Galcanezumab for the Prevention of Episodic Migraine:TheEVOLVE-1RandomizedClinicalTrial,{"}1 published onlineMay29,2018, therewas anerror inTable 1. In the 14th rowof the table, {"}Patients with acute medicationoveruse,{"} thenumberandpercentagevalues should read {"}87 (20.2){"} for the Placebo column; {"}39 (18.3){"} for the Galcanezumab, 120 mg, column; and {"}42 (19.8){"} for the Galcanezumab, 240mg, column. This article was corrected online.",

author = "Stauffer, {V. L.} and Dodick, {D. W.} and Q. Zhang and Carter, {J. N.} and J. Ailani and Conley, {R. R.}",

year = "2019",

month = jul,

doi = "10.1001/jamaneurol.2019.1177",

language = "English (US)",

volume = "76",

pages = "872",

journal = "JAMA neurology",

issn = "2168-6149",

publisher = "American Medical Association",

number = "7",

}

TY - JOUR

T1 - Erratum

T2 - Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212)

AU - Stauffer, V. L.

AU - Dodick, D. W.

AU - Zhang, Q.

AU - Carter, J. N.

AU - Ailani, J.

AU - Conley, R. R.

PY - 2019/7

Y1 - 2019/7

N2 - Error in Table: In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine:TheEVOLVE-1RandomizedClinicalTrial,"1 published onlineMay29,2018, therewas anerror inTable 1. In the 14th rowof the table, "Patients with acute medicationoveruse," thenumberandpercentagevalues should read "87 (20.2)" for the Placebo column; "39 (18.3)" for the Galcanezumab, 120 mg, column; and "42 (19.8)" for the Galcanezumab, 240mg, column. This article was corrected online.

AB - Error in Table: In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine:TheEVOLVE-1RandomizedClinicalTrial,"1 published onlineMay29,2018, therewas anerror inTable 1. In the 14th rowof the table, "Patients with acute medicationoveruse," thenumberandpercentagevalues should read "87 (20.2)" for the Placebo column; "39 (18.3)" for the Galcanezumab, 120 mg, column; and "42 (19.8)" for the Galcanezumab, 240mg, column. This article was corrected online.

UR - http://www.scopus.com/inward/record.url?scp=85066752408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066752408&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2019.1177

DO - 10.1001/jamaneurol.2019.1177

M3 - Comment/debate

C2 - 31135817

AN - SCOPUS:85066752408

SN - 2168-6149

VL - 76

SP - 872

JO - JAMA neurology

JF - JAMA neurology

IS - 7

ER -

Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this